Thrombolytic therapy for central venous catheter occlusion

Haematologica

Volumn 97, Issue 5, 2012, Pages 641-650

  Baskin, Jacquelyn L ^a   Reiss, Ulrike ^b,c   Wilimas, Judith A ^b,c   Metzger, Monika L ^b,c   Ribeiro, Raul C ^b,c   Pui, Ching Hon ^b,c   Howard, Scott C ^b,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Central venous catheter; Obstruction; Occlusion; Thrombolytic agents

Indexed keywords

ALFIMEPRASE; ALTEPLASE; ANISTREPLASE; HEPARIN; PLACEBO; RECOMBINANT UROKINASE; RETEPLASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

ALLERGIC REACTION; ALLERGY; ANAPHYLAXIS; BACTEREMIA; BLEEDING; CATHETER OCCLUSION; CENTRAL VENOUS CATHETERIZATION; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; FIBRINOLYTIC THERAPY; HUMAN; INFECTION; PROPHYLAXIS; REVIEW;

CATHETERIZATION, CENTRAL VENOUS; FIBRINOLYTIC AGENTS; HUMANS; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 84860551425     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.050492     Document Type: Review

References (60)

1. Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM. Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study. J Clin Oncol. 2004;22(13):2718-23.
2. Fratino G, Molinari AC, Parodi S, Longo S, Saracco P, Castagnola E, et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann Oncol. 2005;16(4):648-54.
3. Lokich JJ, Bothe A Jr, Benotti P, Moore C. Complications and management of implanted venous access catheters. J Clin Oncol. 1985;3(5):710-7.
4. Rubin RN. Local installation of small doses of streptokinase for treatment of thrombotic occlusions of long-term access catheters. J Clin Oncol. 1983;1(9):572-3.
5. Tschirhart JM, Rao MK. Mechanism and management of persistent withdrawal occlusion. Am Surg. 1988;54(6):326-8.
6. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? JPEN J Parenter Enteral Nutr. 1995;19(1):75-9.
7. Skinner R, Koller K, Mcintosh N, McCarthy A, Pizer B. Prevention and management of central venous catheter occlusion and thrombosis in children with cancer. Pediatr Blood Cancer. 2008;50(4):826-30.
8. Bagnall-Reeb H. Diagnosis of central venous access device occlusion. implications for nursing practice. J intraven Nurs. 1998;21(5 Suppl):S115-21.
9. Fazeny-Dorner B, Wenzel C, Berzlanovich A, Sunder-Plassmann G, Greinix H, Marosi C, et al. Central venous catheter pinch-off and fracture: recognition, prevention and management. Bone Marrow Transplant. 2003;31(10):927-30.
10. Kerner JA Jr, Garcia-Careaga MG, Fisher AA, Poole RL. Treatment of catheter occlusion in pediatric patients. JPEN J Parenter Enteral Nutr. 2006;30(1 Suppl):S73-81.
11. Hooke C. Recombinant tissue plasminogen activator for central venous access device occlusion. J Pediatr Oncol Nurs. 2000;17(3): 174-8.
12. Werlin SL, Lausten T, Jessen S, Toy L, Norton A, Dallman L, et al. Treatment of central venous catheter occlusions with ethanol and hydrochloric acid. JPEN J Parenter Enteral Nutr. 1995;19(5):416-8.
13. Balestreri L, De Cicco M, Matovic M, Coran F, Morassut S. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur J Radiol. 1995;20(2): 108-11.
14. Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Curr Opin Hematol. 2003;10(5):369-74.
15. Hoshal VL Jr, Ause RG, Hoskins PA. Fibrin sleeve formation on indwelling subclavian central venous catheters. Arch Surg. 1971; 102(4):353-8.
16. Rosovsky RP, Kuter DJ. Catheter-related thrombosis in cancer patients: pathophysi-ology, diagnosis, and management. Hematol Oncol Clin North Am. 2005;19 (1):183-202.
17. Revel-Vilk S, Menahem M, Stoffer C, Weintraub M. Post-thrombotic syndrome after central venous catheter removal in childhood cancer survivors is associated with a history of obstruction. Pediatr Blood Cancer. 2010;55(1):153-6.
18. Revel-Vilk S, Yacobovich J, Tamary H, Goldstein G, Nemet S, Weintraub M, et al. Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer. Cancer. 2010;116 (7):4197-205.
19. Cesaro S, Corro R, Pelosin A, Gamba P, Zadra N, Fusaro F, et al. A prospective survey on incidence and outcome of Broviac/Hickman catheter-related complications in pediatric patients affected by hematological and oncological diseases. Ann Hematol. 2004;83(3):183-8
20. ingram J, Weitzman S, Greenberg ML, Parkin P, Filler R. Complications of indwelling venous access lines in the pedi-atric hematology patient: a prospective comparison of external venous catheters and subcutaneous ports. Am J of Pediatr Hematol Oncol. 1991;13(2):130-6.
21. Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wilcox RG, et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl 3):549S-75S.
22. Deitcher SR, Toombs CF. Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase. Pathophysiol Haemost Thromb. 2005;34(4-5):215-20.
23. Mad Scientist Software. Thrombolytics. Available from: http://www.madsci.com/manu/ches_thr.htm.
24. Rx List: internet drug index. Available from: http://www.rxlist.com/script/main/hp.asp.
25. US Food and Drug Administration -important safety information letter - uroki-nase. Available from: www.fda.gov/down-loads/ucm113563.pdf
26. Squire IB, Lawley W, Fletcher S, Holme E, Hillis WS, Hewitt C, et al. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J. 1999;20(17):1245-52.
27. Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombi-nant tissue plasminogen activator in throm-bosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost. 1994;72(4):543-7.
28. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER. Recombinant tissue plas-minogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol. 2001;12(8):951-5.
29. Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol. 2002;20(1):317-24.
30. Ng R, Li X, Tu T, Semba CP. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients. J Vasc Interv Radiol. 2004;15(1 Pt 1):45-9.
31. Choi M, Massicotte MP, Marzinotto V, Chan AK, Holmes JL, Andrew M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr. 2001;139(1):152-6.
32. Chesler L, Feusner JH. Use of tissue plas-minogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters. J Pediatr Hematol Oncol. 2002;24(8):653-6.
33. Fisher AA, Deffenbaugh C, Poole RL, Garcia M, Kerner JA Jr. The use of alteplase for restoring patency to occluded central venous access devices in infants and children. J Infus Nurs. 2004;27(3):171-4.
34. Jacobs BR, Haygood M, Hingl J. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. J Pediatr. 2001;139(4): 593-6.
35. Blaney M, Shen V, Kerner JA, Jacobs BR, Gray S, Armfield J, et al. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective open-label single-arm study (The Cathflo Activase Pediatric Study). J Vase Interv Radiol. 2006; 17(11 Pt 1):1745-51.
36. Shen V, Li X, Murdock M, Resnansky L, McCluskey ER, Semba CP. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol. 2003;25(l):38-45.
37. Terrill KR, Lemons RS, Goldsby RE. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer. J Pediatr. Hematol. Oncol. 2003;25(ll):864-7.
38. Owens L. Reteplase for clearance of occluded venous catheters. Am J Health Syst Pharm. 2002;59(17):1638-40.
39. Liu CY, Jain V, Shields AF, Heilbrun LK. Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer. J Vase Interv Radiol. 2004;15(1 Pt l):39-44.
40. Gabrail N, Sandler E, Charu V, Anas N, Lim E, Blaney M. et al. TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters. J Vase Interv Radiol. 2010;21(12): 1852-8.
41. Tebbi C, Costanzi J, Shulman R, Dreisbach L, Jacobs BR, Blaney M. et-al. A phase III, open-label, single-arm study of tenecteplase for restoration of function in dysfunctional central venous catheters. J Vase Interv Radiol. 2011;22(8):1117-23.
42. Haire WD, Deitcher SR, Mullane KM, Jaff MR, Firszt CM, Schulz GA, et al. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind placebo-controlled trial. Thromb Haemost. 2004;92(3):575-82.
43. Svoboda P, Barton RP, Barbarash OL, Butylin AA, Jacobs BR, Lata J, et al. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial. Crit Care Med. 2004;32 (10):1990-6.
44. Deitcher SR, Fraschini G, Himmelfarb J, Schuman E, Smith TJ, Schulz GA, et al. Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients. J Vase Interv Radiol. 2004;15(6):575-80.
45. Moll S, Kenyon P, Bertoli L, De Maio J, Homesley H, Deitcher SR. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol. 2006;24(19): 3056-60.
46. Danek GD, Noris EM. Pediatric i.v catheters: efficacy of saline flush. Pediatr Nurs. 1992;18(2):lll-3.
47. Goode CJ, Titler M, Rakel B, Ones DS, Kleiber C, Small S, et al. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nurs Res. 1991;40(6):324-30.
48. LeDuc K. Efficacy of normal saline solution versus heparin solution for maintaining patency of peripheral intravenous catheters in children. J Emerg Nurs. 1997;23(4):306-9.
49. Mitchell MD, Anderson BJ, Williams K, Umscheid CA. Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review. J Adv Nurs. 2009,65(10):2007-21.
50. Gillies H, Rogers HJ, Johnston J, Harper PG, Rudge CJ. Is repeated flushing of Hickman catheters necessary Br Med J (Clin Res Ed). 1985;290(6483):1708.
51. Stephens LC, Haire WD, Tarantolo S, Reed E, Schmit-Pokorny K, Kessinger A, et al. Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). Transfus Sd. 1997;18(2):187-93.
52. Smith S, Dawson S, Hennessey R, Andrew M. Maintenance of the patency of indwelling central venous catheters: is heparin necessary. Am J Pediatr Hematol Oncol. 1991;13(2):141-3.
53. Cesaro S, Tridello G, Cavaliere M, Magagna L, Gavin P, Cusinato R, et al. Prospective, randomized trial of two different modalities of flushing central venous catheters in pediatric patients with cancer. J Clin Oncol. 2009;27(12):2059-65.
54. Kuo YS, Schwartz B, Santiago J, Anderson PS, Fields AL, Goldberg GL. How often should a port-a-cath be flushed- Cancer Invest. 2005;23(7):582-5.
55. Kefeli U, Dane F, Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, et al. Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer. Eur J Cancer Care. 2009;18(2):191-4.
56. Kalmanti M, Germanakis J, Stiakaki E, Syfridaki C, Christidou A, Tsetis D, et al. Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Pediatr Hematol Oncol. 2002;19(3):173-9.
57. Ray CE Jr, Shenoy SS, McCarthy PL, Broderick KA, Kaufman JA. Weekly prophylactic urokinase instillation in tunneled central venous access devices. J Vase Interv Radiol. 1999;10(10):1330-4.
58. Solomon B, Moore J, Arthur C, Prince HM. Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin. Eur J Cancer. 2001;37(18): 2379-84.
59. van Rooden CJ, Schippers EF, Guiot HFL, Barge RM, Hovens MMC, van der Meer FJM, et al. Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol. 2008;26(3):428-33.
60. Aquino VM, Sandler ES, Mustafa MM, Steele JW, Buchanan GR. A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters. J Pediatr Hematol. Oncol. 2002;24(9):710-3.